ArticleThoracic cancer2020
Long-term survival analysis of patients with non-small cell lung cancer complicated with type 2 diabetes mellitus.
Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Survival and predictors of mortality among adults with type 2 diabetes at a teaching hospital in Ghana: a retrospective cohort study.BMC public health · 2026Article
- Analysis of factors influencing lung cancer in patients with type 2 diabetes mellitus.Medicine · 2025Observational
- Mortality Outcomes in People with Lung Cancer with and without Type2 Diabetes: A Cohort Study in England.Clinical epidemiology · 2025Article
- Is a high preoperative HbA1c level a risk factor for postoperative complications in patients with non-small-cell lung cancer?Journal of cardiothoracic surgery · 2024Article
- [Clinical Efficacy Analysis of Wedge Resection of Pulmonary in Patients with Small Volume Invasive Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- Changes in target ability of nanoparticles due to protein corona composition and disease state.Asian journal of pharmaceutical sciences · 2022Article
- Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163.Bioengineered · 2022Article
- Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Small Cell Lung Cancer.International journal of chronic obstructive pulmonary diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThis study aimed to investigate the effect of type 2 diabetes mellitus on survival of patients with non-small cell lung cancer (NSCLC).
methodsWe retrospectively analyzed NSCLC patients who had undergone radical lung cancer surgery from January 2011 to December 2014 in the Anhui Medical University affiliated Anhui Provincial Hospital. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards regression models were used to describe the effect of type 2 diabetes mellitus on the overall survival of patients with NSCLC.
resultsA total of 769 patients with NSCLC were enrolled, including 126 in the diabetic mellitus group and 643 in the nondiabetic mellitus group. The one, three, and five-year survival for patients with and without diabetes mellitus were 86.1% versus 89.6%, 49.5% versus 62.4%, and 33.3% versus 40.6%, respectively. The Cox model showed that type 2 diabetes mellitus was a poor independent prognostic factors for NSCLC patients. In addition, metformin is a good independent prognostic factor for patients with non-small cell lung cancer with type 2 diabetes mellitus.
conclusionsNSCLC patients without type 2 diabetes mellitus have an increased survival rate compared with those with type 2 diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.